BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33121340)

  • 21. HPV testing and vaccination in Europe.
    Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
    J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.
    Demarco M; Lorey TS; Fetterman B; Cheung LC; Guido RS; Wentzensen N; Kinney WK; Poitras NE; Befano B; Castle PE; Schiffman M
    J Low Genit Tract Dis; 2017 Oct; 21(4):261-267. PubMed ID: 28953116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The difference in the effectiveness of human papillomavirus vaccine based on smoking status.
    Hikari T; Honda A; Hashiguchi M; Okuma R; Kurihara M; Fukuda A; Okuma E; Nakao Y; Yokoyama M
    J Obstet Gynaecol Res; 2022 Jul; 48(7):1859-1866. PubMed ID: 35599387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer.
    Castle PE; Fetterman B; Thomas Cox J; Shaber R; Poitras N; Lorey T; Kinney W
    Obstet Gynecol; 2010 Jul; 116(1):76-84. PubMed ID: 20567171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of a Human Papillomavirus Vaccination Program within Organized Cervical Cancer Screening: Cohort Study.
    Martellucci CA; Morettini M; Brotherton JML; Canfell K; Manzoli L; Flacco ME; Palmer M; Rossi PG; Martellucci M; Giacomini G; D'Errico MM; Pasqualini F
    Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):588-594. PubMed ID: 35027435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.
    Larson HJ; Wilson R; Hanley S; Parys A; Paterson P
    Hum Vaccin Immunother; 2014; 10(9):2543-50. PubMed ID: 25483472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of human papillomavirus vaccination in young Japanese girls: the interim results of the OCEAN study.
    Hiramatsu K; Ueda Y; Yagi A; Morimoto A; Egawa-Takata T; Nakagawa S; Kobayashi E; Kimura T; Kimura T; Minekawa R; Hori Y; Sato K; Morii E; Nakayama T; Tanaka Y; Terai Y; Ohmichi M; Ichimura T; Sumi T; Murata H; Okada H; Nakai H; Matsumura N; Mandai M; Saito J; Horikoshi Y; Takagi T; Enomoto T; Shimura K
    Hum Vaccin Immunother; 2022 Dec; 18(1):1951098. PubMed ID: 34802371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
    Joura EA; Garland SM; Paavonen J; Ferris DG; Perez G; Ault KA; Huh WK; Sings HL; James MK; Haupt RM;
    BMJ; 2012 Mar; 344():e1401. PubMed ID: 22454089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Economic effectiveness of vaccination against papilloma virus in the Russian Federation].
    Kostinov MP; Zverev VV
    Zh Mikrobiol Epidemiol Immunobiol; 2012; (2):43-50. PubMed ID: 22693810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-vaccination prevalence of infections with 25 non-high-risk human papillomavirus types among 1,000 Slovenian women in cervical cancer screening.
    Učakar V; Poljak M; Oštrbenk A; Klavs I
    J Med Virol; 2014 Oct; 86(10):1772-9. PubMed ID: 24978445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology.
    Wright TC; Stoler MH; Parvu V; Yanson K; Cooper C; Andrews J
    Gynecol Oncol; 2019 Aug; 154(2):360-367. PubMed ID: 31160073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of human papillomavirus vaccine against cervical precancer in Japan: Multivariate analyses adjusted for sexual activity.
    Kudo R; Sekine M; Yamaguchi M; Hara M; Hanley SJB; Kurosawa M; Adachi S; Ueda Y; Miyagi E; Ikeda S; Yagi A; Enomoto T
    Cancer Sci; 2022 Sep; 113(9):3211-3220. PubMed ID: 35730321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
    Herweijer E; Sundström K; Ploner A; Uhnoo I; Sparén P; Arnheim-Dahlström L
    Int J Cancer; 2016 Jun; 138(12):2867-74. PubMed ID: 26856527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women With Abnormal Cervical Cytology.
    Liu AH; Walker J; Gage JC; Gold MA; Zuna R; Dunn ST; Schiffman M; Wentzensen N
    Obstet Gynecol; 2017 Dec; 130(6):1218-1225. PubMed ID: 29112672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening.
    Song F; Du H; Wang C; Huang X; Qu X; Wei L; Belinson JL; Wu R;
    J Med Screen; 2021 Sep; 28(3):318-324. PubMed ID: 32869705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
    Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
    Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers.
    Dehlendorff C; Baandrup L; Kjaer SK
    J Natl Cancer Inst; 2021 Jul; 113(7):869-874. PubMed ID: 33377930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A questionnaire survey on the prevention of HPV infection among females and males who came of age in Japan under various scenarios of HPV vaccine recommendation.
    Ishimoto T; Yagi A; Nakajima K; Okamoto N; Yukimitsu E; Kawasaki M; Kawae Y; Hayasaka S; Ueda Y; Kimura T
    Hum Vaccin Immunother; 2023 Aug; 19(2):2229222. PubMed ID: 37462048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intentions for catch-up HPV vaccination in Japan: an internet survey.
    Nakagawa S; Yagi A; Ueda Y; Ikeda S; Kakuda M; Hiramatsu K; Miyoshi A; Kimura T; Hirai K; Sekine M; Nakayama T; Kobayashi E; Miyagi E; Enomoto T; Kimura T
    Int J Clin Oncol; 2023 Dec; 28(12):1667-1679. PubMed ID: 37776388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.